Novel Oncolytic Immunotherapy Yields Enduring Responses in High-Risk NMIBC
Cretostimogene grenadenorepvec produced enduring complete responses (CR) among patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), according to data from the phase 3 …